BPTH Stock News 2.67 05/13/2014 18:49:17 Bio-Path Holdings (

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Bio-Path Holdings (BPTH) 2.67 $BPTH

Endo International plc (ENDP) Jumps: Stock Rises 5.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 02, 8:21AM CDT
Endo International plc (ENDP) was a big mover last session, as the company saw its shares rise by over 5% on the day.

Furiex Pharmaceuticals (FURX) Surges: Stock Moves 28.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 8:21AM CDT
Furiex Pharmaceuticals, Inc. (FURX) was a big mover last session, as the company saw its shares rise by roughly 29% on the day.

Global RNAi Drug Delivery Market 2014-2018 with Alnylam Pharmaceuticals, Isis Pharmaceuticals.,Merck & Co & Tekmira Pharmaceuticals Dominating
M2 - Mon Apr 14, 11:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6dhrqp/global_rnai_drug) has announced the addition of the "Global RNAi Drug Delivery Market 2014-2018 with Alnylam Pharmaceuticals, Isis Pharmaceuticals.,Merck & Co & Tekmira Pharmaceuticals Dominating" report to their offering. The Global RNAi Drug Delivery market to grow at a CAGR of 21% to 2018. According to the report, one of the major drivers in this market is the increase in RNA therapeutic development. Therapeutic benefits greatly depend on the efficiency of the RNA delivery to specific diseased cells. This factor is the key to the development of RNAi drug delivery technologies and the market associated with it. Major advances in RNAi drug delivery are aimed at developing better delivery agents with excellent efficacy and the ability to target specific cells. For example, Bio-Path Holdings Inc. developed systemic delivery of antisense, small interfering RNA, and hydrophobic small molecules for treatment of various diseases using its neutral lipid drug delivery technology (neutral liposome). Similarly, Inovio's skin electroporation technology was used for the successful delivery of small interfering RNA molecules to skin in animal studies. Thus, technological innovations would further contribute to the growth of the Global RNAi Drug Delivery market. Further, the report states that one of the major challenges in this market is the targeted delivery of RNA therapeutic molecules. During in vivo drug testing procedures, many companies engaged in developing RNA therapeutics found it difficult to deliver the RNA molecules to specific tissues to bring about a therapeutic effect. Key vendors dominating this space are: - Alnylam Pharmaceuticals Inc. - Isis Pharmaceuticals, Inc - Merck & Co. Inc. - Tekmira Pharmaceuticals Corp.. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/6d..._rnai_drug

3 Humongous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sun Apr 13, 9:30AM CDT
Is the biotech bubble bursting? Maybe -- but certainly not for every biotech stock. Three of the biggest of this week experienced gains of at least 17%. One benefited from positive preliminary data from an early-stage clinical trial. Another surged...

Pacira Pharmaceuticals (PCRX) Soars: Stock Adds 11.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 8:21AM CDT
Pacira Pharmaceuticals, Inc. (PCRX) was a big mover last session, as the company saw its shares rise by over 11% on the day.

Bio-Path Holdings Reports Fiscal Year 2013 Operational and Financial Results
Business Wire - Tue Apr 01, 12:38PM CDT
Bio-Path Holdings, Inc., (NASDAQ:BPTH) ("Bio-Path" , a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced operational and financial results for the year 2013.

Bio-Path Holdings, Inc. Appoints Ulrich W. Mueller Chief Operating Officer
Business Wire - Wed Mar 26, 7:30AM CDT
Bio-Path Holdings, Inc., (NASDAQ:BPTH) ("Bio-Path" , a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that Dr. Ulrich W. Mueller has joined the Company as Chief Operating Officer. Dr. Mueller will be responsible for the Company's drug development, licensing and intellectual property activities, including managing the Company's clinical trials, pre-clinical and research and development efforts.

OTC Markets Group Congratulates Bio-Path Holdings on NASDAQ Listing
PR Newswire - Mon Mar 10, 4:00PM CDT
OTC Markets Group Inc. (OTCQX: OTCM) congratulates Bio-Path Holdings, Inc. on its approval to list on the NASDAQ Capital Market. Bio-Path is moving to NASDAQ from OTCQX®, the best marketplace for qualified companies.

Bio-Path Holdings to trade common stock on NASDAQ Capital Market
M2 - Thu Mar 06, 5:59AM CST
Biotechnology company Bio-Path Holdings (Other OTC:BPTH) stated on Wednesday that its common stock will be listed in the NASDAQ Capital Market following approval.

Bio-Path Holdings Announces Uplisting to the NASDAQ Capital Market
Business Wire - Wed Mar 05, 1:19PM CST
Bio-Path Holdings, Inc., (OTCQX: BPTH) ("Bio-Path" , a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that its shares of common stock have been approved for uplisting to the NASDAQ Capital Market. Effective Monday, March 10, 2014, the stock will trade on the NASDAQ Capital Market under the symbol BPTH.

Global RNAi Drug Delivery Market 2014-2018: Read What's Trending
M2 - Wed Feb 19, 12:15PM CST
Research and Markets (http://www.researchandmarkets.com/research/kv93pj/global_rnai_drug) has announced the addition of the "Global RNAi Drug Delivery Market 2014-2018" report to their offering. The analysts forecast the Global RNAi Drug Delivery market to grow at a CAGR of 21.80 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increase in RNA therapeutic development. The Global RNAi Drug Delivery market has also been witnessing some key technological advancements. However, the targeted delivery of RNA molecules is expected to pose a challenge to the growth of this market. Key vendors dominating this space are Alnylam Pharmaceuticals Inc., Isis Pharmaceuticals, Inc.,Merck & Co. Inc., and Tekmira Pharmaceuticals Corp. Other vendors mentioned in the report are Access Pharmaceuticals Inc., Calondo Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Marina Biotech Inc., PhaseRx Inc., Quark Pharmaceuticals Inc., RXi Pharmaceuticals Corp., Silence Therapeutics plc, Sirnaomics Inc., Tacere Therapeutics Inc., and Traversa Therapeutics Inc. Commenting on the report, an analyst from the team said: Major advances in RNAi drug delivery are aimed at developing better delivery agents with excellent efficacy and the ability to target specific cells. For example, Bio-Path Holdings Inc. developed systemic delivery of antisense, small interfering RNA, and hydrophobic small molecules for treatment of various diseases using its neutral lipid drug delivery technology (neutral liposome). Similarly, Inovio's skin electroporation technology was used for the successful delivery of small interfering RNA molecules to skin in animal studies. Thus, technological innovations would further contribute to the growth of the Global RNAi Drug Delivery market. According to the report, one of the major drivers in this market is the increase in RNA therapeutic development. Therapeutic benefits greatly depend on the efficiency of the RNA delivery to specific diseased cells. This factor is the key to the development of RNAi drug delivery technologies and the market associated with it. For more information visit http://www.researchandmarkets.com/research/kv..._rnai_drug About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Latest Thyroid Cancer Pipeline Review
M2 - Tue Jan 28, 10:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/zmc3df/thyroid_cancer) has announced the addition of the "Thyroid Cancer - Pipeline Review, H2 2013" report to their offering. 'Thyroid Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Thyroid Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Thyroid Cancer. Scope - A snapshot of the global therapeutic scenario for Thyroid Cancer. - A review of the Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Thyroid Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Therapeutics Development - AstraZeneca PLC - GlaxoSmithKline plc - Takeda Pharmaceutical Company Limited - Bio-Path Holdings, Inc. - Eisai Co., Ltd. - Bayer AG - Bionomics Limited - Azaya Therapeutics Incorporated - Vascular Biogenics Ltd. - Biovista Inc. - Trophogen, Inc. - centrose llc - Ecrins Therapeutics SAS For more information visit http://www.researchandmarkets.com/research/zm...oid_cancer

Bio-Path Holdings Inc expects USD10m in registered direct offering
M2 - Fri Jan 17, 10:38AM CST
Biotechnology company Bio-Path Holdings Inc (-OTC Markets:BPTH) said on Thursday that it expects to raise about USD10.0m from the sale of units at USD3.00 per unit in a registered direct offering .

Bio-Path Holdings, Inc. to Raise $10 Million in Registered Direct Offering
Business Wire - Thu Jan 16, 7:00AM CST
Bio-Path Holdings, Inc. (OTCQX: BPTH) (Bio-Path), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, announced today that it is raising approximately $10.0 million in a registered direct offering at a price of $3.00 per unit. The entire offering is being sold to two dedicated healthcare funds that are managed by Sabby Management. Each Unit shall consist of one share of Bio-Path common stock, and a warrant to purchase one half (0.5) of a share of Bio-Path common stock. The common stock and warrants shall be immediately separable. The warrants will be exercisable immediately, have a term of five years and an exercise price of $4.74 per share of common stock. After placement agent fees and estimated offering expenses, the Company expects to receive net proceeds of approximately $9.3 million. The offering is expected to close on or about January 22, 2014, subject to customary closing conditions.

Bio-Path Holdings to Present at the Biotech Showcase(TM) 2014 Conference
Business Wire - Mon Jan 06, 9:59AM CST
Bio-Path Holdings, Inc. (OTCQX: BPTH) ("Bio-Path" , a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that Peter Nielsen, President and Chief Executive Officer, will present a company overview at the Biotech Showcase(TM) 2014 Conference in San Francisco, Calif., on Wednesday, January 15, 2014 at 8:00 a.m. Pacific Time.

Preliminary Results from Bio-Path Holdings' Phase I Clinical Trial Presented at the Annual Meeting of the American Society of Hematology (ASH) in New Orleans
Business Wire - Mon Dec 09, 10:20AM CST
Bio-Path Holdings, Inc., (OTCQX: BPTH) ("Bio-Path" , a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, announced that Dr. Jorge Cortes, deputy chair and professor of medicine in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, presented Phase I data from Bio-Path's clinical trial evaluating its lead product candidate, Liposomal Grb-2 (BP-100-1.01), in hematological cancers at the 55th Annual Meeting of the American Society of Hematology (ASH) in New Orleans.

Bio-Path Holdings Reports Third Quarter 2013 Operational and Financial Results
Business Wire - Fri Nov 15, 12:30PM CST
Bio-Path Holdings, Inc., (OTCQX: BPTH) ("Bio-Path" , a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced operational and financial results for the third quarter ended September 30, 2013.

Bio-Path Holdings Inc retains Maxim Group LLC as investment banking firm
M2 - Fri Sep 20, 8:00AM CDT
Biotechnology company Bio-Path Holdings Inc (OTC Markets:BPTH) reported on Thursday that it has hired Maxim Group LLC as its financial advisor again for its next phase.

Bio-Path Holdings, Inc. Retains Investment Banking Firm Maxim Group LLC
Business Wire - Thu Sep 19, 8:30AM CDT
Bio-Path Holdings, Inc., (OTCQX: BPTH) ("Bio-Path" , a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it has retained Maxim Group LLC, as a financial advisor. Maxim will focus on assisting Bio-Path in its strategies for maximizing shareholder value through its full scope of investment banking services.

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w6k5cg/acute_myelocytic) has announced the addition of the "Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2013" report to their offering. 'Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). Scope - A snapshot of the global therapeutic scenario for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). - A review of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Genzyme Corporation Johnson & Johnson Boehringer Ingelheim GmbH F. Hoffmann-La Roche Ltd. Amgen Inc. Sanofi-Aventis AstraZeneca PLC Eli Lilly and Company GlaxoSmithKline plc Seattle Genetics, Inc. Genentech, Inc. Gilead Sciences, Inc. Daiichi Sankyo Company, Ltd medac GmbH Merck & Co., Inc. Gamida Cell Ltd. Generex Biotechnology Corporation Plexxikon Inc. BioLineRx, Ltd. Bio-Path Holdings, Inc. Millennium Pharmaceuticals, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/w6...myelocytic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Telit Cinterion Tests Its Defense Connectivity Pitch

Updated Category News Views 107

Defense connectivity is a messy business, and Telit Cinterion is leaning straight into the mess at NATO Edge 2026 in Izmir, Turkey. From November 17 through 19, the company is using Booth L86 to show how several wireless links can live inside one mission-focused setup. That may sound like standard trade-show wallpaper, but the underlying problem is very real: military and...

Continue Reading
Hyster-Yale's $125 Million Convertible Debt Shuffle

Updated Category News Views 86

Forklifts do not make headlines often, but debt terms sure can. Hyster-Yale has proposed a $125 million private offering of convertible senior notes due November 15, 2031, with buyers able to take another $18.75 million if the initial purchasers exercise their option. For NYSE:HY holders, this is not a victory lap or a distress flare by itself. It is a refinancing...

Continue Reading
Innoviz's 1-for-20 Split Is a Listing Lifeline Test

Updated Category News Views 45

A twenty-share pile of INVZ is about to become one share, and nobody should confuse that paperwork with a turnaround. Innoviz plans to enact a 1-for-20 reverse split at 11:59 p.m. Eastern on Friday, December 4, with split-adjusted trading expected when Nasdaq opens on December 7. This is a blunt instrument aimed at one immediate problem: getting the quoted share price...

Continue Reading
Sectra's RSNA AI Pitch Centers on Workflow, Not Hype

Updated Category News Views 121

Radiology has heard enough grand AI promises to fill a hospital basement, which makes Sectra's RSNA 2026 message refreshingly grounded. The Swedish imaging IT and cybersecurity company is putting its weight behind the unglamorous part of adoption: fitting AI into the daily diagnostic machinery without handing clinicians another awkward system to babysit. That is where...

Continue Reading
Sysco's Northern California Labor Deal Gets Bigger

Updated Category News Views 20

One hundred forty-four drivers may not rattle a giant food distributor by themselves, but labor agreements have a habit of growing legs. Sysco's Northern California and Nevada regional contract has added members from Teamsters Locals 386 and 431, bringing its coverage above 1,100 workers. For investors watching Sysco, this is less about one afternoon's headline and more...

Continue Reading
Oracle Takes AI to Construction's Messy Project Middle

Updated Category News Views 164

A stalled drywall inspection can wreck a schedule faster than any glossy AI pitch can repair it. That is the grimy, practical corner Oracle is aiming at with its latest Oracle Primavera Cloud upgrades: the daily hunt for answers, the repeated logging of familiar risks, and the finger-pointing that starts when a milestone is suddenly in danger. This is not a chatbot being...

Continue Reading
Cadence Marks $2.7 Million for St. Jude Family Care

Updated Category News Views 112

Small Wheels, Serious Purpose Tiny tricycles, flour-dusted bake-sale tables, and family pledges have pushed Cadence Education’s St. Jude partnership to $2.7 million since 2018. That number is not a flashy balance-sheet item, nor should anybody try to dress it up as one. It is the accumulated result of school communities showing up year after year, and in a sector built...

Continue Reading
Elijah Craig Uses AI Toasts to Sell a Warmer Pour

Updated Category News Views 38

A Speech Prompt With a Bourbon Label Few things expose holiday nerves faster than a raised glass and a room waiting for somebody to say something memorable. Elijah Craig has decided that awkward little moment is marketing territory, rolling out its Digital Perfect Pour, Perfect Toast Generator for mobile and desktop users ahead of the holiday season. The tool asks for a...

Continue Reading
TORM Rejects Hafnia's No-Premium Merger Pitch Again

Updated Category News Views 112

A 19.8% shareholder heading for the exit can rattle a shipping stock before breakfast, and TORM has answered the noise with a flat refusal to pretend Hafnia's merger approach was good enough. The message from Hellerup on November 18 is unusually blunt: Hafnia made several conditional, all-share proposals, TORM saw no effective premium for control, and the board rejected...

Continue Reading
Gozney Brings in Armin Boehm for a Global Growth Push

Updated Category News Views 95

A pizza oven company has just made a very grown-up management move. Gozney appointed Armin Boehm as Global President, effective from October 31, putting an experienced consumer-brand operator beside founder, designer and CEO Tom Gozney at a moment when the business says it is becoming a global omnichannel operation. This is not the sort of announcement that comes with...

Continue Reading

Top 5 Most Recently Viewed Articles

Shell PLC's Strategic Share Repurchase Program Explained

Updated Category News Views 198

Understanding Shell PLC's Share Repurchase Strategy Shell plc has recently made headlines with its ongoing share buyback program. On a notable date, the company announced a significant purchase of its own shares intended for cancellation. This action is a part of its broader strategy to enhance shareholder value and optimize its capital structure. Details of the Share...

Continue Reading
Teck Resources Faces Maintenance Challenges at Chile Operations

Updated Category News Views 255

Maintenance Updates from Teck Resources Limited Teck Resources Limited (TSX: TECK.A and TECK.B, NYSE: TECK) has recently reported important updates regarding maintenance challenges at its operations in Chile. A mechanical issue has emerged at the Carmen de Andacollo (CdA) site, necessitating a temporary shutdown of the SAG mill. According to the latest information,...

Continue Reading
Neinor Homes Achieves FY24 Targets and New Shareholder Returns

Updated Category News Views 151

Neinor Homes Achieves Fiscal Targets for 2024 In a recent update, Neinor Homes reports successful fulfillment of its Adjusted Net Income target of €65 million for fiscal year 2024. The company, known for its prominence in residential property development, is now poised for continued growth. With the expected announcement of its fiscal results set for the latter part of...

Continue Reading
STG Logistics Staff Earn Supply Chain Accolades

Updated Category News Views 41

There's a fresh breeze running through the corridors of STG Logistics. Why? Because two of their own have snagged some serious recognition with the 2026 Women in Supply Chain Awards. This isn't just another blip on the corporate radar—it's a salute to the powerhouse of leadership and innovation nestled within the company's ranks. Geoff Anderman, the CEO himself, was...

Continue Reading
WISeKey International Holding Ltd Unveils AGM Agenda for Stakeholders

Updated Category News Views 284

WISeKey International Holding Ltd Unveils AGM Agenda for Stakeholders WISeKey International Holding Ltd, recognized for its significant contributions in the fields of cybersecurity and IoT, has announced the essential items for consideration by its shareholders at the upcoming Annual General Meeting (AGM). This important gathering, set to foster engagement between...

Continue Reading